DCM Shriram Board Approves ₹856 Cr FY26 Profit, Recommends ₹4 Dividend, Sanctions ₹101 Cr Capex

Consolidated Profit After Tax (PAT) for the year ended March 31, 2026, stood at ₹855.98 crore; Standalone PAT was ₹837.55 crore.
Reader Takeaway: Capacity boost signals growth; shareholder nod key for full dividend payout.

What just happened (today’s filing)

DCM Shriram's Board of Directors met on May 13, 2026, to approve the audited financial results for the fiscal year ending March 31, 2026.

The company reported a consolidated Profit After Tax (PAT) of ₹855.98 crore and a standalone PAT of ₹837.55 crore for FY26.

A final dividend of ₹4 per equity share has been recommended. This brings the total dividend for FY26 to ₹11.20 per share, amounting to a total payout of ₹174.66 crore.

Crucially, the Board approved a capital investment of ₹101 crore for its subsidiary, Hindusthan Specialty Chemicals Ltd (HSCL), aimed at augmenting its Formulated Resins capacity.

The company also approved the cancellation of 39,00,000 forfeited equity shares, subject to shareholder approval at the upcoming Annual General Meeting (AGM).

Why this matters

The investment in HSCL underscores DCM Shriram's focus on expanding its Value-added businesses, particularly in the Advanced Materials segment within its Chemicals portfolio.

This expansion aims to increase Formulated Resins capacity by 36,000 TPA, taking the total capacity to 50,000 TPA, positioning the company to capture growing demand in specialty chemicals.

The proposed dividend signals a commitment to shareholder returns, reflecting the company's profitability and cash flow generation capabilities.

The backstory (grounded)

DCM Shriram has been strategically enhancing its specialty chemicals division, a move aligned with industry trends favouring value-added products.

This focus on capacity expansion in advanced materials and niche chemical products is part of a broader strategy to drive margin expansion and sustainable growth.

What changes now

Shareholders are set to receive a final dividend of ₹4 per share, contributing to a total FY26 payout of ₹11.20 per share.

The ₹101 crore capital expenditure at HSCL will boost Formulated Resins capacity, potentially leading to increased revenue and market share in this segment.

This investment signals continued confidence in the growth prospects of DCM Shriram's chemicals business.

The company is seeking shareholder approval for the final dividend and the cancellation of forfeited shares at the AGM on August 18, 2026.

Risks to watch

The effective implementation of the ₹101 crore capacity expansion project at HSCL will be critical for realizing its growth potential.

The final dividend payout and the cancellation of forfeited shares are contingent on shareholder approval at the upcoming AGM.

Peer comparison

Companies like Pidilite Industries and Aarti Industries are also actively expanding their specialty chemical offerings, indicating a competitive landscape.

DCM Shriram's focus on Formulated Resins places it in a segment that requires continuous innovation and strong R&D capabilities, similar to peers.

Context metrics (time-bound)

• The total dividend payout for FY26 is ₹11.20 per equity share, an increase from ₹10.00 per share in FY25.
• Consolidated Profit After Tax grew from ₹800.00 crore in FY25 to ₹855.98 crore in FY26.

What to track next

Shareholder approval at the 37th AGM on August 18, 2026, for the recommended final dividend and cancellation of forfeited shares.

Progress updates on the ₹101 crore capacity expansion project for Formulated Resins at HSCL.

Future performance metrics of the Chemicals business, especially the Advanced Materials segment.

Any further strategic announcements or investment plans related to HSCL or other subsidiaries.